Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZX-101A in Relapsed/Refractory Hematological Malignancies
NCT05269940Phase 2Completed
- Sponsor
- Zenshine Pharmaceuticals Co., Ltd.
- Start
- Feb 2022
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ZX-101A in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), non-Hodgkin lymphoma (NHL) and 2 more (5 arms), sponsored by Zenshine Pharmaceuticals Co., Ltd. Primary endpoints: Recommended Phase 2 Dose up to 2 years and Incidence of Adverse Events up to 2 years. Started Feb 2022; status: completed.
02
Drugs
ZX-101A
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)non-Hodgkin lymphoma (NHL)peripheral T-cell lymphoma (PTCL)cutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on NCT05269940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05269940.